School of Biomedical Engineering, Sun Yat-sen University, Shenzhen 518107, China
wujun29@mail.sysu.edu.cn
收稿:2021-12-24,
修回:2022-01-20,
录用:2022-01-24,
网络首发:2022-05-05,
纸质出版:2022-09-01
Scan QR Code
Meng, Y. B.; Wu, J. Facile and one-step direct synthesis of poly(valine) as a robust drug nanocarrier for enhanced breast cancer therapy. Chinese J. Polym. Sci. 2022, 40, 1016–1027
Ya-Bin Meng, Jun Wu. Facile and One-step Direct Synthesis of Poly(valine) as a Robust Drug Nanocarrier for Enhanced Breast Cancer Therapy[J]. Chinese Journal of Polymer Science, 2022, 40(9): 1016-1027.
Meng, Y. B.; Wu, J. Facile and one-step direct synthesis of poly(valine) as a robust drug nanocarrier for enhanced breast cancer therapy. Chinese J. Polym. Sci. 2022, 40, 1016–1027 DOI: 10.1007/s10118-022-2701-9.
Ya-Bin Meng, Jun Wu. Facile and One-step Direct Synthesis of Poly(valine) as a Robust Drug Nanocarrier for Enhanced Breast Cancer Therapy[J]. Chinese Journal of Polymer Science, 2022, 40(9): 1016-1027. DOI: 10.1007/s10118-022-2701-9.
In this study an easy-operating but effective strategy is used to prepare PVal which can self-assemble into nanoparticles (PVal-NPs
~104 nm) by nanoprecipitation and have a higher drug payload for tumor chemotherapy. This nanoplatform is stable under physiological conditions and could induce the apoptosis of 4T1 cells like free DOX while alleviating its toxicity. The in vivo evaluation indicated that DOX@PVal-NPs have a high tumor accumulation
penetration and therapeutic performance after intravenous injection without causing toxicity to main organs. Overall
this study provides a new strategy for synthesis of poly(amino acid)s as drug carrier to deliver antitumor drugs.
Synthetic poly(amino acid)s with good biodegradable and biocompatible properties have attracted increased attention as carriers in biomedical applications in recent years
their synthesis and purification procedures are usually complicated and some by-products would occur yet. Given this
polypeptide with good biodegradable and biocompatible properties is prepared and optimized by one-step and direct synthesis strategy and poly(valine) (PVal) is selected here as a model polypeptide in this study. This newly generated PVal can self-assemble into poly(valine) nanoparticles (PVal-NPs) with a high drug-loading capacity (
>
20 wt%) of doxorubicin (DOX) and shows strong cytotoxicity against 4T1 cells. Upon cellular internalization
the release of DOX could be accelerated by the endosomal acidic environment which leads to enhanced anticancer effects. The results
in vivo
show that DOX@PVal-NPs have a long blood circulation time
high cancer accumulation and penetration
and good therapeutic performance in 4T1 tumor-bearing mice without causing obvious adverse effect on main organs. With these combined advantages
these PVal-based nanoplatform would provide an effective drug delivery tool for clinical breast cancer therapy.
Sung, H.; Ferlay, J.; Siegel, R . L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries . CA Cancer J. Clin. , 2021 . 71 209 - 249 . DOI: 10.3322/caac.21660 http://doi.org/10.3322/caac.21660 .
Nanda, R.; Chow, L. Q. M.; Dees, E. C.; Berger, R.; Gupta, S.; Geva, R.; Pusztai, L.; Pathiraja, K.; Aktan, G.; Cheng, J . D.; Karantza, V.; Buisseret, L. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study . J. Clin. Oncol. , 2016 . 34 2460 - 2467 . DOI: 10.1200/JCO.2015.64.8931 http://doi.org/10.1200/JCO.2015.64.8931 .
da Silva, J. L.; Nunes, N. C. C.; Izetti, P.; de Mesquita, G. G.; de Melo, A. C . Triple negative breast cancer: a thorough review of biomarkers . Crit. Rev. Oncol./Hematol. , 2020 . 145 102855 DOI: 10.1016/j.critrevonc.2019.102855 http://doi.org/10.1016/j.critrevonc.2019.102855 .
Li, S.; Wu, Y.; Ding, F.; Yang, J.; Li, J.; Gao, X.; Zhang, C.; Feng, J . Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer . Nanoscale , 2020 . 12 10854 - 10862 . DOI: 10.1039/d0nr00523a http://doi.org/10.1039/d0nr00523a .
Schmid, P.; Adams, S.; Rugo, H. S.; Schneeweiss, A.; Barrios, C. H.; Iwata, H.; Dieras, V.; Hegg, R.; Im, S. A.; Wright, G. S.; Henschel, V.; Molinero, L.; Chui, S. Y.; Funke, R.; Husain, A.; Winer, E. P.; Loi, S.; Emens, L. A.; Investigators, I. M. T . Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer . New Engl. J. Med. , 2018 . 379 2108 - 2121 . DOI: 10.1056/NEJMoa1809615 http://doi.org/10.1056/NEJMoa1809615 .
Fan, J. L.; Liu, B.; Long, Y.; Wang, Z.; Tong, C. Y.; Wang, W.; You, P. D.; Liu, X. M . Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition . Acta Biomater. , 2020 . 113 554 - 569 . DOI: 10.1016/j.actbio.2020.06.025 http://doi.org/10.1016/j.actbio.2020.06.025 .
Zhang, H.; Fei, J. B.; Yan, X. H.; Wang, A. H.; Li, J. B. Enzyme-responsive release of doxorubicin from monodisperse dipeptide-based nanocarriers for highly efficient cancer treatment in vitro . Adv. Funct. Mater. 2015, 25 , 1193-1204.
Xiong, F.; Ling, X.; Chen, X.; Chen, J.; Tan, J.; Cao, W.; Ge, L.; Ma, M.; Wu, J . Pursuing specific chemotherapy of orthotopic breast cancer with lung metastasis from docking nanoparticles driven by bioinspired exosomes . Nano Lett. , 2019 . 19 3256 - 3266 . DOI: 10.1021/acs.nanolett.9b00824 http://doi.org/10.1021/acs.nanolett.9b00824 .
Guo, P.; Yang, J.; Liu, D. X.; Huang, L.; Fell, G.; Huang, J.; Moses, M. A.; Auguste, D. T . Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis . Sci. Adv. , 2019 . 5 eaav5010 DOI: 10.1126/sciadv.aav5010 http://doi.org/10.1126/sciadv.aav5010 .
Zhang, Y. J.; Zhu, X.; Chen, X. L.; Chen, Q. J.; Zhou, W. X.; Guo, Q.; Lu, Y. F.; Li, C.; Zhang, Y.; Liang, D. H.; Sun, T.; Wei, X. B.; Jiang, C . Activated platelets-targeting micelles with controlled drug release for effective treatment of primary and metastatic triple negative breast cancer . Adv. Funct. Mater. , 2019 . 29 1806620 DOI: 10.1002/adfm.201806620 http://doi.org/10.1002/adfm.201806620 .
Ding, J.; Chen, J.; Gao, L.; Jiang, Z.; Zhang, Y.; Li, M.; Xiao, Q.; Lee, S. S.; Chen, X . Engineered nanomedicines with enhanced tumor penetration . Nano Today , 2019 . 29 100800 DOI: 10.1016/j.nantod.2019.100800 http://doi.org/10.1016/j.nantod.2019.100800 .
Tao, W.; Zeng, X. W.; Wu, J.; Zhu, X.; Yu, X. H.; Zhang, X. D.; Zhang, J . X.; Liu, G.; Mei, L. Polydopamine-based surface modification of novel nanoparticle-aptamer bioconjugates for in vivo breast cancer targeting and enhanced therapeutic effects . Theranostics , 2016 . 6 470 - 484 . DOI: 10.7150/thno.14184 http://doi.org/10.7150/thno.14184 .
Wolfram, J.; Ferrari, M . Clinical cancer nanomedicine . Nano Today , 2019 . 25 85 - 98 . DOI: 10.1016/j.nantod.2019.02.005 http://doi.org/10.1016/j.nantod.2019.02.005 .
Meng, Q. S.; Meng, J.; Ran, W.; Wang, J. Y.; Zhai, Y. H.; Zhang, P. C.; Li, Y. P . Light-activated core-shell nanoparticles for spatiotemporally specific treatment of metastatic triple-negative breast cancer . ACS Nano , 2018 . 12 2789 - 2802 . DOI: 10.1021/acsnano.7b09210 http://doi.org/10.1021/acsnano.7b09210 .
Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C . Cancer nanomedicine: progress, challenges and opportunities . Nat. Rev. Cancer , 2017 . 17 20 - 37 . DOI: 10.1038/nrc.2016.108 http://doi.org/10.1038/nrc.2016.108 .
Zhang, Y . J.; Sun, T.; Jiang, C. Biomacromolecules as carriers in drug delivery and tissue engineering . Acta Pharm. Sin. B , 2018 . 8 34 - 50 . DOI: 10.1016/j.apsb.2017.11.005 http://doi.org/10.1016/j.apsb.2017.11.005 .
Schnaider, L.; Brahmachari, S.; Schmidt, N. W.; Mensa, B.; Shaham-Niv, S.; Bychenko, D.; Adler-Abramovich, L.; Shimon, L. J. W.; Kolusheva, S.; DeGrado, W. F.; Gazit, E . Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity . Nat. Commun. , 2017 . 8 1365 DOI: 10.1038/s41467-017-01447-x http://doi.org/10.1038/s41467-017-01447-x .
Deming, T. J . Synthesis of side-chain modified polypeptides . Chem. Rev. , 2016 . 116 786 - 808 . DOI: 10.1021/acs.chemrev.5b00292 http://doi.org/10.1021/acs.chemrev.5b00292 .
Zhong, P.; Qiu, M.; Zhang, J.; Sun, H.; Cheng, R.; Deng, C.; Meng, F.; Zhong, Z . cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma . Nanotechnology , 2017 . 28 295103 DOI: 10.1088/1361-6528/aa76cc http://doi.org/10.1088/1361-6528/aa76cc .
Wan, G. Y.; Cheng, Y. Y.; Song, J.; Chen, Q.; Chen, B. W.; Liu, Y. Y.; Ji, S. L.; Chen, H. L.; Wang, Y. S . Nucleus-targeting near-infrared nanoparticles based on TAT peptide-conjugated IR780 for photo-chemotherapy of breast cancer . Chem. Eng. J. , 2020 . 380 122458 DOI: 10.1016/j.cej.2019.122458 http://doi.org/10.1016/j.cej.2019.122458 .
Zhou, H.; Lv, S.; Zhang, D.; Deng, M.; Zhang, X.; Tang, Z.; Chen, X . A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity . Acta Biomater. , 2018 . 73 388 - 399 . DOI: 10.1016/j.actbio.2018.04.016 http://doi.org/10.1016/j.actbio.2018.04.016 .
Tao, J.; Dang, M.; Su, X. D.; Hao, Q.; Zhang, J. J.; Ma, X. B.; Lu, G. M.; Zhang, Y. L.; Tian, Y.; Weng, L. X.; Teng, Z. G.; Wang, L. H . Facile synthesis of yolk-shell structured monodisperse mesoporous organosilica nanoparticles by a mild alkalescent etching approach . J. Colloid Interface Sci. , 2018 . 527 33 - 39 . DOI: 10.1016/j.jcis.2018.05.024 http://doi.org/10.1016/j.jcis.2018.05.024 .
Meng, F.; Wang, J.; Ping, Q.; Yeo, Y . Quantitative assessment of nanoparticle biodistribution by fluorescence imaging, revisited . ACS Nano , 2018 . 12 6458 - 6468 . DOI: 10.1021/acsnano.8b02881 http://doi.org/10.1021/acsnano.8b02881 .
0
浏览量
237
Downloads
4
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802046900号